The Series A financing will allow for acceleration in the development of EnfiniT – a ‘transformational’ suite of technologies designed around a novel epigenetic antigen discovery engine, able to detect unique cancer antigens – and a next generation CAR-T cell therapy platform, which reportedly combines pioneering research from Institut Curie and Memorial Sloan Kettering Cancer Center.
“Mnemo Therapeutics is on an ambitious mission to transform the lives of patients made possible by the technological leadership of our scientific founders, Dr Sebastian Amigorena, CNRS researcher at Institut Curie and Dr Michel Sadelain of Memorial Sloan Kettering Cancer Center,” explained Alain Maiore, CEO of Mnemo Therapeutics.
“Based on the support from our premier investors and our team’s deep experience, we have completed a record-breaking Series A financing in France to develop powerful cell therapies that will achieve unprecedented breakthroughs for patients with solid and blood-based cancers,” Maiore continued.
You may also be interested in:
- [NEWS] Next-Generation Car-T, Car-M and NK/NKT Platform Launched, Focussed On Curing Difficult-To-Treat Cancers
- [INTERVIEW] A Regulator's View of CAR-T Approval with Dr Paula Salmikangas, EMA
- [TALK] Demonstrating a Successful CAR-T Commercialisation Partnership with a Clinical Centre
When the CAR-T cell therapy platform is combined with EnfiniT technologies capable of increasing CAR-T cell memory and persistence, the team reports a range of therapeutic opportunities are enabled that can ‘deliver deeper clinical responses’ than cell therapies currently available.
The EnfiniT platform is hoped to be able to overcome limitations currently associated with CAR-T, facilitating the creation and development of highly effective and scalable cell therapies.
Antoine Papiernik, Managing Partner and Chairman of returning investor, Sofinnova Partners commented:
Eli Casdin, Chief Investment Officer and Founder of Casdin Capital concluded:
“Our belief in Mnemo’s unique, integrated approach to cell therapy compelled us to spearhead the seed round in 2019. Now, more than ever, we are confident in its potential to deliver a new treatment standard across a range of solid tumours and blood cancers, with the ability to impact other devastating diseases. We are delighted to welcome a strong syndicate of international investors who now join us to support the power and promise of Mnemo’s ground-breaking technology.”
Source: Mnemo Therapeutics press release
“Cell therapy is a fast moving field and the next generation of therapies requires smarter, stronger T cells with superior sensitivity for tumour-specific antigens. We believe Mnemo has both and have been incredibly impressed with the scientific and technological capability at the company. We look forward to supporting the team as they significantly advance the field of CAR T and bend the mortality curve on hard to treat cancers.”